SCHEMBL257549

SCHEMBL257549

Cc1cc2[nH]c(=O)cc(-c3ccc(Cl)cc3)n2n1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.74
RAB9A P51151 3/20 0.74
MAPK1 P28482 2/20 0.49
KDM4E B2RXH2 3/20 0.44
HPGD P15428 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 2/20 0.44
PARP1 P09874 2/20 0.43
CYP1A2 P05177 1/20 0.43
TP53 P04637 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ARF6 P62330 2/20 0.39
PTGS2 P35354 1/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
PLAT P00750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256938 0.86 NPC1 (0.74) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL257697 0.83 NPC1 (0.67) NPC1RAB9AMAPK1KDM4EHPGD
SCHEMBL257543 0.79 NPC1 (0.77) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL257310 0.78 NPC1 (0.68) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL15043143 0.77 NPC1 (0.49) NPC1RAB9AMAPK1KDM4EHPGD
SCHEMBL461719 0.73 NPC1 (0.59) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL10072120 0.70 ARF6 (0.53) MAPK1TP53MEN1KMT2ASMN1; SMN2
SCHEMBL15020774 0.70 NPC1 (0.60) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL5461696 0.70 NPC1 (0.56) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL11061300 0.70 CA12 (0.50) NPC1RAB9AKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 NPC1 114/4885RAB9A 542/4885MAPK1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.